Editas Medicine Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $585.56 million
- Book Value:
- Revenue TTM:
- $19.71 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Editas Medicine Inc had its IPO on 2016-02-03 under the ticker symbol EDIT.
The company operates in the Healthcare sector and Biotechnology industry. Editas Medicine Inc has a staff strength of 226 employees.
Shares of Editas Medicine Inc opened at $8.45 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $8.11 - $8.45, and closed at $8.37.
This is a -1.41% slip from the previous day's closing price.
A total volume of 1,901,700 shares were traded at the close of the day’s session.
In the last one week, shares of Editas Medicine Inc have increased by +2.07%.
Editas Medicine Inc's Key Ratios
Editas Medicine Inc has a market cap of $585.56 million, indicating a price to book ratio of 1.7176 and a price to sales ratio of 26.3844.
In the last 12-months Editas Medicine Inc’s revenue was $19.71 million with a gross profit of $-155246000 and an EBITDA of $-219612992. The EBITDA ratio measures Editas Medicine Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Editas Medicine Inc’s operating margin was -1146.26% while its return on assets stood at -23.7% with a return of equity of -48.22%.
In Q4, Editas Medicine Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 47.6%.
Editas Medicine Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.19 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Editas Medicine Inc’s profitability.
Editas Medicine Inc stock is trading at a EV to sales ratio of 12.2468 and a EV to EBITDA ratio of -1.5875. Its price to sales ratio in the trailing 12-months stood at 26.3844.
Editas Medicine Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $514.32 million
- Total Liabilities
- $60.11 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Editas Medicine Inc ended 2023 with $514.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $514.32 million while shareholder equity stood at $360.68 million.
Editas Medicine Inc ended 2023 with $0 in deferred long-term liabilities, $60.11 million in other current liabilities, 7000.00 in common stock, $-1078131000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $141.52 million and cash and short-term investments were $344.27 million. The company’s total short-term debt was $11,082,000 while long-term debt stood at $0.
Editas Medicine Inc’s total current assets stands at $356.75 million while long-term investments were $93.10 million and short-term investments were $202.75 million. Its net receivables were $5.15 million compared to accounts payable of $9.51 million and inventory worth $0.
In 2023, Editas Medicine Inc's operating cash flow was $-27528000.00 while its capital expenditure stood at $624000.
Comparatively, Editas Medicine Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Editas Medicine Inc stock is currently trading at $8.37 per share. It touched a 52-week high of $21.595 and a 52-week low of $21.595. Analysts tracking the stock have a 12-month average target price of $13.06.
Its 50-day moving average was $9.18 and 200-day moving average was $12.06 The short ratio stood at 10.74 indicating a short percent outstanding of 0%.
Around 47.7% of the company’s stock are held by insiders while 8210.4% are held by institutions.
Frequently Asked Questions About Editas Medicine Inc
Similar Industry Stocks (Biotechnology)
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.